PDE4 Allosteric Modulator Program
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pre-clinicalActive
Key Facts
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase
Pre-clinical
Status
Active
Company
About Mironid
Mironid is a private, preclinical-stage biotech developing first-in-class small molecules for ADPKD and other rare diseases with high unmet need. Its core technology involves the allosteric modulation of long-form PDE4 enzymes, a novel mechanism intended to be disease-modifying. Led by an experienced team with backgrounds at Merck, GSK, and other biopharma firms, the company is building a pipeline and positioning itself as a future leader in PDE therapeutics. Mironid is currently pre-revenue and focused on advancing its research programs to key value inflection points.
View full company profileTherapeutic Areas
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxypurinol (XRX-OXY) | XORTX Therapeutics | Phase 3 |
| TAK-186 (Goreisan) | Takeda | Phase 2 |
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| Small Molecule Potentiator Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| Tamibarotene | Rege Nephro | Preclinical |
| Tolvaptan | Otsuka Holdings | Approved |
| PXL-770 | Scynexis | Phase 2-ready |